Last reviewed · How we verify

Metformin-Sitagliptin-Empaglifozin-Pioglitazone

Azienda Ospedaliero-Universitaria di Parma · Phase 3 active Small molecule

Metformin-Sitagliptin-Empaglifozin-Pioglitazone is a Oral antidiabetic combination (metformin + DPP-4 inhibitor + SGLT2 inhibitor + thiazolidinedione) Small molecule drug developed by Azienda Ospedaliero-Universitaria di Parma. It is currently in Phase 3 development for Type 2 diabetes mellitus (combination therapy). Also known as: POLYCHEM.

This four-drug combination targets multiple pathways in glucose metabolism: metformin reduces hepatic glucose production, sitagliptin enhances incretin signaling, empaglifozin increases urinary glucose excretion, and pioglitazone improves insulin sensitivity.

This four-drug combination targets multiple pathways in glucose metabolism: metformin reduces hepatic glucose production, sitagliptin enhances incretin signaling, empaglifozin increases urinary glucose excretion, and pioglitazone improves insulin sensitivity. Used for Type 2 diabetes mellitus (combination therapy).

At a glance

Generic nameMetformin-Sitagliptin-Empaglifozin-Pioglitazone
Also known asPOLYCHEM
SponsorAzienda Ospedaliero-Universitaria di Parma
Drug classOral antidiabetic combination (metformin + DPP-4 inhibitor + SGLT2 inhibitor + thiazolidinedione)
TargetMultiple: AMPK/mitochondrial (metformin), DPP-4 (sitagliptin), SGLT2 (empaglifozin), PPAR-γ (pioglitazone)
ModalitySmall molecule
Therapeutic areaDiabetes
PhasePhase 3

Mechanism of action

Metformin is a biguanide that decreases hepatic gluconeogenesis and improves peripheral insulin sensitivity. Sitagliptin is a DPP-4 inhibitor that prolongs GLP-1 and GIP action to stimulate glucose-dependent insulin secretion. Empaglifozin is an SGLT2 inhibitor that promotes renal glucose excretion. Pioglitazone is a thiazolidinedione that activates PPAR-γ to enhance insulin sensitivity in muscle and adipose tissue. Together, these agents provide complementary glycemic control through distinct mechanisms.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Metformin-Sitagliptin-Empaglifozin-Pioglitazone

What is Metformin-Sitagliptin-Empaglifozin-Pioglitazone?

Metformin-Sitagliptin-Empaglifozin-Pioglitazone is a Oral antidiabetic combination (metformin + DPP-4 inhibitor + SGLT2 inhibitor + thiazolidinedione) drug developed by Azienda Ospedaliero-Universitaria di Parma, indicated for Type 2 diabetes mellitus (combination therapy).

How does Metformin-Sitagliptin-Empaglifozin-Pioglitazone work?

This four-drug combination targets multiple pathways in glucose metabolism: metformin reduces hepatic glucose production, sitagliptin enhances incretin signaling, empaglifozin increases urinary glucose excretion, and pioglitazone improves insulin sensitivity.

What is Metformin-Sitagliptin-Empaglifozin-Pioglitazone used for?

Metformin-Sitagliptin-Empaglifozin-Pioglitazone is indicated for Type 2 diabetes mellitus (combination therapy).

Who makes Metformin-Sitagliptin-Empaglifozin-Pioglitazone?

Metformin-Sitagliptin-Empaglifozin-Pioglitazone is developed by Azienda Ospedaliero-Universitaria di Parma (see full Azienda Ospedaliero-Universitaria di Parma pipeline at /company/azienda-ospedaliero-universitaria-di-parma).

Is Metformin-Sitagliptin-Empaglifozin-Pioglitazone also known as anything else?

Metformin-Sitagliptin-Empaglifozin-Pioglitazone is also known as POLYCHEM.

What drug class is Metformin-Sitagliptin-Empaglifozin-Pioglitazone in?

Metformin-Sitagliptin-Empaglifozin-Pioglitazone belongs to the Oral antidiabetic combination (metformin + DPP-4 inhibitor + SGLT2 inhibitor + thiazolidinedione) class. See all Oral antidiabetic combination (metformin + DPP-4 inhibitor + SGLT2 inhibitor + thiazolidinedione) drugs at /class/oral-antidiabetic-combination-metformin-dpp-4-inhibitor-sglt2-inhibitor-thiazolidinedione.

What development phase is Metformin-Sitagliptin-Empaglifozin-Pioglitazone in?

Metformin-Sitagliptin-Empaglifozin-Pioglitazone is in Phase 3.

What are the side effects of Metformin-Sitagliptin-Empaglifozin-Pioglitazone?

Common side effects of Metformin-Sitagliptin-Empaglifozin-Pioglitazone include Hypoglycemia, Gastrointestinal disturbance (metformin-related), Genital mycotic infections (empaglifozin-related), Fluid retention and weight gain (pioglitazone-related), Urinary tract infection.

What does Metformin-Sitagliptin-Empaglifozin-Pioglitazone target?

Metformin-Sitagliptin-Empaglifozin-Pioglitazone targets Multiple: AMPK/mitochondrial (metformin), DPP-4 (sitagliptin), SGLT2 (empaglifozin), PPAR-γ (pioglitazone) and is a Oral antidiabetic combination (metformin + DPP-4 inhibitor + SGLT2 inhibitor + thiazolidinedione).

Related